Heron Patrick J

Director Patrick J Heron buys 131,425 MIRM shares for $8,999,984 at $68.48; stock now at $99.27, up 25.2% in 30 days

Patrick J Heron, a director of Mirum Pharmaceuticals, purchased 131,425 shares at $68.48 on 2026-01-23, expanding his holdings by 40.1% to 459,010 shares total with a transaction value of $8,999,984.00. The stock has since rallied to $99.27, representing 25.2% appreciation in just 30 days and 40.9% over 90 days, approaching the 52-week high. Critically, Heron's prior 5 open-market purchases at MIRM (all in March 2025) demonstrated a consistent pattern: each buy was followed by positive 90-day returns ranging from +7.0% to +13.0%, establishing a 100% win rate at this specific ticker on the 90-day timeframe. Against this backdrop of sustained revenue growth of 80.8% year-over-year and a substantial director stake accumulation, this large, discretionary purchase signals conviction in Mirum's trajectory, though the company remains unprofitable on a full-year basis despite recent quarterly profitability of $2.9M.

Director Heron Patrick J purchased 666,666 shares of MBX at $18.00 for $11,999,988.00 ($12.0M), expanding stake to 5,219,440 shares (+14.6%), while company reported $-19,411,000 net loss.

Director Heron Patrick J made a substantial $12.0M open-market purchase of 666,666 shares at $18.00, increasing his holdings by 14.6% from 4,552,774 to 5,219,440 shares. The purchase occurred at a price 2.9% above the current market price of $17.50, and notably within a 52-week range where the stock now stands 32.6% below its high. His cross-ticker track record shows 20 prior buys with an average 90-day return of +2.5% and a 60% win rate, suggesting a historically inconsistent track record for buy timing. However, MBX Biosciences remains unprofitable with a full-year net income of $-19,411,000, meaning the fundamental backdrop is deteriorating even as the insider significantly increased exposure.

Director Patrick J Heron bought 2,646 shares of ARQT at $13.08; stock down 23.3% from 52-week high; 4 prior buys in 8 trading days

Patrick J Heron, a Director, purchased 2,646 shares at $13.08 on 2025-06-13, bringing his holdings to 27,448 shares and representing a 10.7% increase in his position. This transaction is noteworthy because it is the fifth open-market purchase by Heron in an 8-trading-day window (buys on 2025-05-15, 2025-05-21, 2025-05-22, 2025-06-04, and 2025-06-05), totaling accumulation during a period when the stock has declined 6.0% over 30 days and 20.1% over 90 days, now trading 23.3% below its 52-week high of $17.29. While Heron's cross-ticker track record shows a 75.00% win rate over 20 prior buys, his same-ticker history at ARQT reveals mixed near-term outcomes: one measurable buy (2025-05-15) posted a -1.4% 30-day return. The repeated purchases during a downtrend, combined with the company's unprofitable status (latest full-year net income: $-25,060,000.00 on revenue of $65,846,000.00) and current valuation relative to recent price action, warrant attention to whether the timing and concentration of these acquisitions align with a fundamental thesis or represent standard portfolio management.

Director Heron Patrick J bought 2,268 shares at $13.34 avg (2 purchases June 4-5), increasing stake to 24,802 shares (+10.1%)

Director Heron Patrick J completed 2 separate purchases totaling 2,268 shares for $30,246.73 at a blended average price of $13.34 on June 4-5, 2025, increasing his post-transaction holdings to 24,802 shares. The stock is currently trading at $14.37, approximately 7.7% above his entry price. His prior 5 trades at ARQT (May 13-22) occurred in an even more compressed timeframe and outcomes are not yet measurable, making it unclear whether this latest purchase reflects conviction about near-term catalysts or represents part of a broader accumulation pattern. The company generated $65.8M in quarterly revenue with significant annual growth of +229.7%, but remains unprofitable with a net loss of $25.1M most recent quarter, leaving fundamental momentum uncertain despite revenue expansion.

Director Patrick J Heron bought 5,040 shares at avg $13.66 (May 21-22), increasing holdings 28.8% to 22,534 shares.

Director Patrick J Heron executed 2 purchases totaling 5,040 shares for $68,821.20 on consecutive days (May 21-22) at $13.66 average price, increasing his position from 17,494 to 22,534 shares. The transaction occurred at $13.66 per share, below the current price of $13.98 and substantially below the 52-week high of $17.29. His prior same-ticker trades at ARQT (5 previous buys) occurred in rapid succession immediately before this filing (May 9, 13, 14, 15), suggesting a sustained period of accumulation. His cross-ticker track record shows 66.67% 90-day win rate with +5.0% average 90-day return, though only 1 of his prior ARQT trades has a measurable 90-day outcome (-12.0% on the March 2024 purchase), indicating limited predictive value at this specific ticker. The company remains unprofitable (net income: $-25.1M in latest quarter) despite strong revenue growth of +229.7% annually, presenting a higher-risk growth-stage asset where insider accumulation warrants observation of whether near-term fundamentals or cash runway concerns drive the sustained buying pattern.

Director Heron Patrick J buys 2,520 shares of ARQT at $13.62; aggressive accumulation after 3 prior purchases in 5 days.

Director Heron Patrick J executed his fourth purchase of ARQT in five calendar days (2025-05-09 through 2025-05-15), buying 2,520 shares at $13.62 and bringing his post-transaction holdings to 17,494 shares (+16.8% net change). This clustering of buys within a narrow window stands out against his cross-ticker track record, where 20 prior buys averaged a -0.8% return in the 30-day window following purchase. At the same ticker, his only measurable prior trade (2024-03-04) yielded a -12.0% return after 90 days, indicating no pattern of well-timed entries at this company. Arcutis is unprofitable (net income of $-25,060,000.00 in its most recent full fiscal year) but grew revenue +229.7% year-over-year, and the stock has risen +17.0% over 90 days from the earliest of these purchases. The director's willingness to accumulate repeatedly through a near-term window despite unfavorable historical timing outcomes at this ticker warrants close tracking of motivation and competitive positioning.

Director Patrick J Heron bought 8,674 shares at $13.76 (2 transactions, $119.4K), raising stake 137.7% to 15.0K shares.

Patrick J Heron, a director at Arcutis Biotherapeutics, executed 2 separate purchases totaling 8,674 shares for $119,351.93 at $13.76 per share on 2025-05-13 and 2025-05-14, growing his holdings from 6,300 to 14,974 shares—a 137.7% increase in position size. The stock currently trades at $13.63, near the transaction price, and sits 21.2% below its 52-week high of $17.29. Arcutis is an unprofitable biotech company with revenue of $65,846,000.00 (latest quarter) and a net loss of $25,060,000.00, though it showed strong annual revenue growth of +229.7%. Heron's cross-ticker trading history shows 20 prior open-market buys with a 75.00% 90-day win rate and average 90-day return of +5.5%, but his prior trades at Arcutis have been less predictive: his single measurable prior buy at this ticker on 2024-03-04 returned -12.0% over 90 days. The timing of this large open-market accumulation near recent highs and the company's ongoing unprofitability warrant monitoring of how this fundamental backdrop develops.

Director Patrick J Heron buys 6,300 shares of ARQT at $13.60; entry at -20.1% from 52-week high, stock up 9.8% in 30 days.

Patrick J Heron, a director, purchased 6,300 shares at $13.60 on 2025-05-09, establishing a new position in Arcutis. The purchase came after the stock had declined significantly from its 52-week high of $17.29, with the stock now at $13.82 (a -20.1% pullback from peak). Notably, this director's cross-ticker track record shows 20 prior buys with a 77.78% win rate over 90 days (avg 90d return +7.2%), though his prior ARQT buy in March 2024 returned -12.0% at the 90-day mark. The company is unprofitable (net income $-25.1M in latest quarter) but growing rapidly (annual revenue growth +229.7%), creating a mix of execution risk and top-line momentum that warrants investor attention to both the insider's conviction and the underlying business fundamentals.

Director Patrick J Heron bought 549 shares at $44.11 avg (2 transactions, $24.2K), holding 168.7K shares post-transaction at MIRM

Patrick J Heron, a Director at Mirum Pharmaceuticals, executed 2 separate purchases totaling 549 shares for $24,214.01, with transaction prices at $44.11 and $43.93 on March 14–17, 2025. The company has generated strong revenue growth of +80.8% year-over-year and posted quarterly revenue of $90,377,000.00, but remains unprofitable with a net loss of $-14,235,000.00 in the latest quarter. The insider's cross-ticker track record shows a 77.78% win rate with an average 90-day return of +7.2% across 17 prior buys; however, his 5 prior trades at MIRM (all purchases on March 6–11) lack measurable outcomes and do not yet establish a same-ticker pattern. The stock is currently trading at $44.31, down 16.6% from its 52-week high of $53.16 and down 11.4% over the past 30 days, though up 9.1% over 90 days, suggesting recent volatility in an unprofitable but fast-growing biotech name.

Director Patrick J Heron bought 2,298 shares at avg $43.31 over 3 days; stock +6.5% YTD but unprofitable.

Patrick J Heron, a Director at Mirum Pharmaceuticals, executed 3 separate purchases totaling 2,298 shares for $99,517.93 across March 10–11, 2025, at an average price of $43.31 per share. His holdings increased from 165,825 to 168,123 shares (+1.4%), and the current price of $45.03 stands 15.3% below the 52-week high of $53.16. The buying occurs as the stock has declined 10.8% over the past 30 days, though it is up 6.5% over 90 days and the company has posted strong annual revenue growth of +80.8%; however, Mirum remains unprofitable with negative net income of $-14,235,000.00 in the latest quarter. The director's cross-ticker track record shows a 77.78% win rate with average 90-day returns of +7.2%, but his same-ticker history at MIRM shows 5 prior buys within the preceding days (March 4–7, 2025), none yet measurable at the 90-day horizon, suggesting a pattern of accumulation during a period of stock weakness.